Innovations + Investments in Healthcare Summit 2015


NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

For more information visit

Nycomed RSS Channel

Title Filter      Display #  
# Article Title
1 Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
2 Nycomed reports double-digit growth across emerging markets in second quarter 2011
3 Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
4 Nycomed continues to outperform in emerging markets in first quarter 2011
5 Nycomed acquires distribution rights to product portfolio in Turkey
6 REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment
7 Nycomed well positioned in emerging markets
8 Nycomed's novel COPD therapy roflumilast receives FDA approval
9 Nycomed to acquire Colombian company Farmacol
10 Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
11 Nycomed is keeping the pace in third quarter 2010
12 Nycomed to accelerate expansion in China
13 Global market launch of Daxas® (Roflumilast) kicks off in Germany
14 Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union
15 Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas®
16 Nycomed and Baxter receive FDA approval for TachoSil®
17 Nycomed on track in 2009 with strong growth in Key Products
18 Nycomed reports continued satisfactory performance in the third quarter 2009
19 Nycomed reports sustained momentum in second quarter 2009
20 Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]